Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Gilead 4Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Gilead 4Q

Product sales increased 30% to a record $1.8 billion in 4Q09.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Gilead 4Q

4Q Revenues: $2.0 billion (+42%)

4Q Earnings: $802.2 million (+43%)

FY Revenues: $7.0 billion (+31%)

FY Earnings: $2.6 billion (+33%)

Comments: Product sales increased 30% to a record $1.8 billion in 4Q09. Growth was driven by the company’s antiviral franchise, with strong growth in sales of Atripla and Truvada. Antiviral product sales were up 27% to $1.6 billion in the quarter. Truvada sales were $670.7 million (+19%). Viread sales were up 10% to $178.3 million. Royalty, contract and other revenues primarily from collaborations, were $228.0 million, up from $40.4 million in 4Q08. For the year, product sales were up 27% to $6.5 billion.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters